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Summary 
The leukocyte response integrin (LRI) is a phagocyte integrin which recognizes the basement 
membrane protein entactin and the synthetic peptide Lys-Gly-Ala-Gly-Asp-Val  (KGAGDV). The 
function of LRI is intimately associated with that of a distinct membrane protein, integrin- 
associated protein (IAP),  as antibodies which recognizes IAP can inhibit all known functions 
of LRI. When adherent to a surface, the LtLI ligands entactin and KGAGDV activate the respiratory 
burst in polymorphonuclear leukocytes (PMN) and monocytes, as do monoclonal antibodies (mAb) 
directed at either LRI or IAP. When added in solution, peptides and antibodies specific for LRI, 
and some, but not all, anti-lAP antibodies,  can inhibit the respiratory  burst activated by any 
of these surface-adherent ligands. Only monoclonal anti-lAP antibodies which can inhibit LRI 
function when added in solution are competent to activate the respiratory burst when adherent 
to a surface. KGAGDV peptide and anti-LRI added in solution can inhibit anti-lAP-stimulated 
respiratory burst. The LRI-IAP-initiated respiratory burst is independent of CD18, as judged 
by: (a) blockade of inhibition by anti-CD18  mAb with the protein kinase A inhibitor HA1004; 
(b) enhanced sensitivity of CD18-dependent respiratory burst compared with LRI/IAP-dependent 
respiratory burst to the tyrosine kinase inhibitors  genestein and herbimicin;  and (c) generation 
of a respiratory burst in response to KGAGDV, anti-LRI, and anti-lAP coated surfaces in PMN 
from a patient with LAD. Despite its apparent CD18 independence, LRI/IAP-initiated respiratory 
burst requires a solid phase ligand and is sensitive to cytochalasin B. These data suggest a model 
in which LKI and lAP act together as a single signal transduction unit to activate the phagocyte 
respiratory  burst, in a manner that requires CD18-independent cell adhesion. 
C 
irculating peripheral blood monocytes and neutrophils 
(PMN) 1 are in a resting state, consuming little energy 
or oxygen, minimally phagocytic,  and poorly adherent.  In 
contrast, at extravascular sites of inflammation, phagocytes 
achieve an "activated" phenotype, with greatly increased ox- 
ygen consumption, generation of toxic oxygen metabolites, 
and markedly increased phagocytic and adhesive potential. 
A variety of molecules found at inflammatory sites may signal 
this switch to the activated, inflammatory phenotype, among 
which are chemotaxins,  arachidonate metabolites, and lyso- 
phospholipid. Extracellular matrix proteins, such as fibronectin 
and laminin, also are potent inducers of the inflammatory 
1 Abbreviations used in this paler: Br-cAMP, 8-bromoadenosine 3':5"-cyclic 
monophosphate; HPO, hydrogen peroxide oxoreductase; IAP, integrin- 
associated protein; KRPG, Krebs buffer with glucose; LR.I, leukocyte 
response integrin;  opd, o-phenylenediamine; PLL, poly-t-lysine; PMN, 
peripheral blood neutrophils; RM, reaction mixture. 
phenotype. These proteins can stimulate enhanced phagocy- 
tosis directly, whether immobilized on a surface or in solu- 
tion (1-3) and, on a surface, can sensitize cells for generation 
of the respiratory  burst (4, 5). Teleologically, these effects 
of phagocyte interaction with extraceUular matrix can be en- 
visioned as signals to the cell that it has left the vasculature 
and entered tissue where maximum inflammatory and host 
defense functions are required (6). Many of these effects of 
extracellular matrix on phagocyte biology require the con- 
tribution of f12 (CD18)-containing integrin receptors (4, 5, 
7). Recently, a leukocyte integrin receptor for multiple ex- 
traceUular matrix proteins has been described which mediates 
activation of phagocytic cells from the resting to the inflam- 
matory phenotype but is not a f12 integrin (1, 8). This inte- 
grin receptor, termed the leukocyte response integrin (LRI) 
is immunologically related to the/~3 integrin family. LRI 
recognizes the Arg-Gly-Asp sequence in a number of extracel- 
lular matrix proteins and via this interaction signals activa- 
tion of phagocytic function (1, 8), adhesion, and chemotaxis 
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Asp sequence, Lys-Gly-Ala-Gly-Asp-Val  (KGAGDV), which 
is not a ligand for any other known integrin (8). All known 
functions of  LRI, including binding of  multivalent KGAGDV 
ligands, can be specifically inhibited by antibodies to a distinct 
50-kD  single  chain  membrane  protein  termed  integrin- 
associated protein (IAP) (2, 8).  This has led to the hypoth- 
esis that IAP is a component of the signal transduction cas- 
cade for phagocyte activation beginning with LRI ligation 
(10). However, experimental systems to test this hypothesis 
have been lacking. 
In the current work, we have developed  an experimental 
system to explore the signal transduction cascade initiated 
by LRI ligation. To do this, we have examined assembly of 
the NADPH oxidase in monocytes and PMN in response 
to ligation of LRI or IAP.  We show that ligation of LRI 
by surface-bound ligands and antibodies will directly acti- 
vate the respiratory burst in PMN and monocytes. Activa- 
tion can be inhibited by LRI ligands or antibodies added as 
competitors in solution, mAbs recognizing some, but not 
all, epitopes of IAP are equally potent inhibitors of the LRI- 
initiated respiratory burst when added in solution. These same 
antibodies against IAP will activate the respiratory burst when 
attached to a surface. LRI-directed ligands and antibodies in 
solution can inhibit this anti-lAP mAb initiated respiratory 
burst. These data demonstrate that LRI and IAP act as a signal 
transduction unit in the generation of a phagocyte respira- 
tory burst. This suggests that IAP may be analogous to the 
"extra chain" of cytokine receptors: a nonligand-binding com- 
ponent which influences both ligand affinity  and signal trans- 
duction (11-15). The signal transduction cascade initiated by 
LRI/IAP can be distinguished pharmacologically from the 
CD18-dependent activation pathway. These data demonstrate 
that there exists a novel integrin-dependent mechanism for 
activation of PMN at sites of inflammation and infection. 
Materials and Methods 
Reagents.  The following reagents were purchased: Scopoletin, 
poly-t-lysine (PLL), PMA, 0-phenylenediamine  (opd), cytochalasin 
B,  8-bromoadenosine Y:S"-cyclic monophosphate  (Br-cAMP), 
hydrogen peroxide oxoreductase  (HPO), and Ficoll-Hypaque  were 
from Sigma Chemical Co. (St. Louis, MO); protein A was from 
Pharmada Fine Chemicals  (Piscataway,  NJ); H-7 and HA1004 were 
from Seikagaku America, Inc. (St. Petersburg, FL); genestein and 
herbimicin were from GIBCO BRL (Gaithersburg, MD); horse- 
radish peroxidase (HRP)-conjugated  goat anti-mouse IgG was from 
Amersham Corp. (Arlington Heights, IL); and dimethylsulfoxide 
was from Aldrich Chemical Co. (Milwaukee, WI). 
Buffers.  PBS was from Biowhittaker (Walkersville,  MD). Krebs- 
Ringer buffer (KRPG) was 145 mM NaC1, 4.86 mM KC1, 1.22 
mM MgSO4, 5.7 mM Na2HPO4, 0.54 mM CaCI2, and 5.5 mM 
glucose, pH 7.4. 
Ligands.  Fibronectin was from the New York Blood Center 
(New York, NY); mouse laminin, purified from the EHS sarcoma, 
was the kind gift of Dr. Hynda Kleinman (National Institute of 
Dental Research/National Institutes of Health, Bethesda, MD); 
recombinant, baculovirus-produced  entactin was from (Upstate Bio- 
technology  Inc., Lake  Placid, NY); the branched peptides KGAGDV 
and KGALEV were prepared using fmoc chemistry as previously 
described (2, 8). 
Monodonal Antibodies.  The following mAbs were used in these 
studies: IB4 (anti-CD18) (16); 3D9 (anti-CD 35) (17); W6/32 (anti- 
HI,  A) (18); 7G2 (anti-/33 [CD61]) (1); and anti-lAP mAb B6H12, 
2D3, and 1F7 (1, 2). IB4 and 3D9 IgG were purified from ascites 
using octanoic add as described (19). W6/32, 7G2, B6H12, and 
2D3 IgG were prepared using a bioreactor (Amicon Corp., Danvers, 
MA) according to the manufacturer's instructions. SDS-PAGE of 
all purified IgG preparations showed them to be >90%  IgG. 
Phagocyte Isolation.  Human PMN  were isolated by dextran 
sedimentation and Ficoll-Hypaque density centrifugation as de- 
scribed (20). PMN were obtained from a/32 integrin-defidency  pa- 
tient followed at Baylor College of Medicine (Waco, TX) (patient 
10 [21]). The patient's blood and a normal control were transported 
and the PMN prepared as described (22). Peripheral blood mono- 
cytes were isolated by countercurrent elutriation, exactly as previ- 
ously described (23). 
Preparation of Ligand- and mAb-coated Plates.  96-well tissue cul- 
ture plates (Costar, Cambridge, MA) were coated with protein A 
and then mAb essentially according to the method of Berton et 
al. (7). Briefly, PLL-coated  wells were incubated with 100/zg/ml 
protein A. After washing, the protein A-coated wells  were incubated 
with various mAb at 20 #g/ml for 4 h or overnight at 4~  In 
preliminary experiments, binding of all the mAb used in this study 
to these wells was evaluated  by ELISA using goat anti-mouse IgG 
to detect bound antibody. As described by Berton et al. (7), pro- 
tein A-coated wells bound significantly  more mAb than uncoated 
wells, regardless of the isotype of the mAb (see Fig. 1). For the 
mAb used in this study, there was no reproducible difference  be- 
tween protein A and protein G coating. At 20 #g/ml, all anti- 
bodies bound to protein A-coated wells equivalently (Fig. 1). 
To coat wells with protein or peptide ligands, Immulon 2 plates 
(Dynatech, Chantilly,  VA) were incubated  with 300 #g/ml entactin, 
50/zg/ml fibronectin or laminin, or 150/~g/ml synthetic peptide 
in PBS at 4~  overnight. After washing with PBS, the plates were 
blocked with 2 mg/ml casein  at room temperature for 2 h and then 
with 10% heat-inactivated FCS in PBS for 40 min. 
1-1202 Assay.  The microwell H202 assay  was adapted from the 
method of De la Harpe and Nathan (24), as modified by Berton 
et al. (7). Briefly,  50,000 PMN or monocytes in 20 #1 KRPG were 
added to wells that already contained 80/zl of a reaction mixture 
(RM) for the detection of products of the respiratory burst. RM 
consisted of 37.5 /~M scopoletin, 1.25 mM NAN3, 1.25 U/ml 
HPO in KRPG, which also contained potential activators or in- 
hibitors of the respiratory burst. After addition of the cells, gener- 
ation of H202 was detected by the decrease in fluorescence of 
scopoletin as  measured on  a  Cytofluor  2300 microtiter  plate 
fluorimeter (Millipore Continental Water Systems, Bedford, MA) 
using an excitation wavelength of 360 nm and an emission wave- 
length of  460 mn. Both excitation  and emission  filters  had a nominal 
band pass of 40 nm. Measurement of fluorescence  was performed 
immediately and then every 15 min during kinetic assays and at 
the end of 60 min for endpoint assays. During the intervals be- 
tween measurements,  plates  were covered  with foil and kept at 37~ 
Specific release of H202 was determined by comparison to a stan- 
dard curve, as previously  described  (24). For each  experimental  group 
data were collected from triplicate wells. 
Pretreatment of PMN.  PMN at 2.5  x  106 cells/ml in KRPG 
were pretreated with 2.5/zg/ml ofmAb or 100/~g/ml of synthetic 
peptide at 4~  for 15 min. Without washing, PMN were added 
to antibody- or ligand-coated  plates containing RM. For treatment 
with pharmacologic  agents, PMN were preincubated  with HA1004 
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Figure  1.  mAb binding to protein A immunized on tissue culture phtes. 
The binding of the various mAbs used in this study to wells coated with 
protein A ([]) is compared to wells incubated with PBS alone (D). Anti- 
body binding was detected in both cases  with HRP-linked  goat anti-mouse 
IgG. Protein A coating leads to increased  binding of all mAb to the wells, 
and approximately  equivalent binding of  all mAb regardless of  IgG subtype. 
at 1/~M, herbimicin at 10/~g/ml, genestein at 50 Itg/ml, H-7 at 
300 nM, or cAMP at 100 IzM, at 37°C for 15 min, and then added 
to RM containing the same concentration of the indicated agent. 
In experiments examining the effects ofcytochalasin B, PMN were 
pretreated with 2.5/~g/ml cytochalasin  B and added to RM con- 
taining no additional drug. In some experiments,  PMA (50 ng/ml) 
was added  to RM simultaneously with PMN. 
Results 
Adhesive LRI Ligands Activate the Respiratory Burst in PMN 
and Monocytes.  LRI on PMN binds the basement membrane 
protein  entactin  (9)  and  recognizes  the  peptide  sequence 
KGAGDV (8).  We examined whether  these ligands could 
activate the respiratory burst when bound to a surface. Each 
ligand 1=t to significant generation of HzOz in the microwell 
assay by both PMN (Fig. 2) and monocytes (Fig. 3). In con- 
trast, as previously described (4), the extracellular matrix pro- 
teins fibronectin and laminin did not elicit a respiratory burst, 
nor did the ligand-related control peptide KGALEV. The ki- 
netics of entactin- and KGAGDV-stimulated respiratory burst 
were similar and did not show the lag phase characteristic 
of TNF-ot or F-Met-Leu-Phe-stimulated adherent PMN (4, 
5).  The respiratory burst  stimulated by these LRI ligands 
was inhibited by mAb 7G2, directed toward LRI, and mAb 
B6H12, directed toward IAP. The mAb 2D3, which recog- 
nizes lAP but unlike B6H12 does not inhibit LRI-dependent 
enhancement of phagocytosis or KGAGDV ligand binding 
(2, 8), also did not inhibit LRI-dependent respiratory burst 
(Fig. 4). mAb W6/32 (anti-HLA) and 3D9 (anti-CR1) also 
had no effect on peptide- or entactin-stimulated respiratory 
burst,  even  though both antibodies  recognize cell  surface 
receptors on PMN  and monocytes (Fig.  4). 
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Figure 2.  LRI ligands stimulate the respiratory burst in PMN. The 
generation of H2Oz by PMN incubated in wells coated with various ex- 
tracellular matrix ligands or controls is compared kinetically (A) and at 
60 min (B). The LRI ligands entactin and KGAGDV  peptide activate a 
PMN respiratory  bunt, while the proteins laminin and fibronectin, as weU 
as the control peptide KGALEV, do not. (A) A single experiment per- 
formed in triplicate. (B) Data shown are the mean _+ SEM of measure- 
ments at 60 min from three independent experiments, each performed in 
triplicate. Maximal respiratory  burst stimulated with 50 ng/ml PMA was 
2.5  _+  0.4 nmol HzO2 at 60 min. 
Anti-LRI and Anti-lAP Antibodies  Activate the Respiratory 
Burst.  Recently,  Berton et al. (7) showed that  surface ad- 
herent anti-CD18 mAb could activate the PMN respiratory 
burst as a substitute for ligand. Surface-bound anti-LRI mAb 
7G2 activated both PMN (Fig.  5) and monocyte (data not 
shown) respiratory burst to similar levels as the anti-CD18 
mAb IB4. Anti-lAP mAb B6H12-stimulated H202 produc- 
tion by phagocytes to the same extent and with the same 
kinetics as the anti-fl3 mAb 7G2 (Fig.  5).  The noninhibi- 
tory anti-lAP mAb 2D3,  which recognizes a distinct epi- 
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Figure 4.  Inhibition of the KGAGDV-stimulated respiratory burst. 
PMN, pretreated with buffer (control), various mAb at 2.5 /xg/ml, or 
peptides at 100/~g/ml for 15 min at 4~  were  incubated in wells coated 
with KGAGDV  peptide. The generation  of H202 was quantitated at 60 
min. Data shown are the mean _+ SEM of three  independent  experiments 
performed in triplicate. 7G2, B6H12, and KGAGDV  peptide inhibit the 
respiratory  burst stimulated  by adherent  KGAGDV,  whereas  W6/32, 3D9, 
and the noninhibitory  anti-lAP mAb 2D3 do not. 
Figure  3.  LR.I  ligands stimulate the respiratory  burst in monocytes. 
The generation  of H202 by freshly  isolated peripheral  blood monocytes 
incubated on wells coated  with various extracellular  matrix ligands and 
controls is compared kinetically (.4) and at 60 min (/3). Entactin and 
KGAGDV peptide stimulate respiratory  burst activity  in monocytes,  but 
laminin, fibronectin,  and KGALEV  do not. (A) A single  experiment  per- 
formed in triplicate  is shown￿9  (B) Data shown are the mean _+ SEM of 
measurements at 60 min from three independent  experiments,  each per- 
formed in triplicate. 
tope from B6H12 (2), did not activate the respiratory burst 
in the same assay, even though it recognizes IAP with similar 
affnity to B6H12 (2, 25). 1F7, a second inhibitory anti-lAP 
mAb, activated the PMN respiratory burst to the same ex- 
tent and with similar kinetics as B6H12 (data not shown). 
Consistent with previous data (7), the anti-HLA mAb W6/32 
did not activate the respiratory burst in either monocytes or 
PMN,  nor did the anti-CR1  mAb  3D9. 
Next, we examined the ability of LR.I ligands, and anti- 
LR.I or anti-lAP mAb, added in solution, to inhibit respira- 
tory burst. When added in solution, mAb 7G2 (anti-/33) and 
B6H12 (anti-lAP), as well as the peptide KGAGDV, inhibited 
7G2-stimulated respiratory burst (Fig. 6 A). These reagents 
had no effect on anti-CD18-stimulated respiratory burst (Fig. 
6 B). As controls, the irrelevant anti-HLA mAb W6/32, the 
noninhibitory anti-lAP mAb 2D3, and the inactive peptide 
KGALEV were used. None affected H2Oz generation by ei- 
ther stimulus. These data show that anti-LRI, anti-lAP, and 
the LRI ligand KGAGDV specifically inhibit the respiratory 
burst stimulated by surface-adherent LRI ligands and anti- 
bodies, presumably through competition with the substrate- 
bound activators. 
LRI L igands and A nti-LRI Antibodies Inhibit the Respiratory 
Burst Stimulated by Anti-lAP Antibodies.  The ability of B6H12 
to stimulate the respiratory burst directly when attached to 
a surface demonstrated that IAP was directly involved in the 
activation pathway. This observation also allowed a distinction 
among possible mechanisms of signal transduction through 
LRI and IAP.  If IAP were activated after ligand binding to 
LRI, soluble LRI ligands and antibodies should not inhibit 
direct activation of respiratory burst by anti-lAP antibody. 
Alternatively, if IAP and LRI were components of a single 
signal transduction complex, LRI ligands in solution should 
compete with plate bound anti-lAP mAb and inhibit gener- 
ation of the respiratory burst as they did when KGAGDV 
or 7G2 was  the stimulating ligand in the solid phase.  In- 
deed,  KGAGDV  and  7G2  in  solution  inhibited  B6H12- 
stimulated respiratory burst (Fig.  7). These data are consis- 
tent with the hypothesis that LRI and IAP act as a signal 
transduction complex and are inconsistent with a hypothesis 
in which IAP activation is downstream from LRI ligation. 
Anti-CDl8 Inhibits LRI/IAP-stimulated Respiratory Burst via 
cAMP.  As ligation of the CD18 receptors LFA-1 and p150,95 
has been shown to activate the respiratory burst (7), it was 
necessary to determine whether CD18 integrins had a role 
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Figure  5.  Surface-bound  7G2 and B6H12 stimulate the respiratory burst 
in PMN. The generation of H202 by PMN incubated in wells coated with 
various mAb is compared kinetically (.4) and at 60 min (/3). mAb II34 
stimulates the PMN respiratory bunt, as reported (7). 7G2 and B6H12 
also stimulate a respiratory  burst, whereas mAb which bind to PMN but 
recognize unrelated antigens (31)9 and W6/32) do not. Surprisingly, the 
anti-lAP mAb 2I)3, which is not inhibitory  when added in solution, cannot 
stimulate a respiratory  burst when adherent to a protein A-coated surface. 
(.4) A single experiment performed in triplicate is shown. (B) Data shown 
are the mean _+ SEM of measurements at 60 min from three independent 
experiments, each performed in triplicate. 
in respiratory burst activation via the LRI/IAP complex. The 
anti-CD18 mAb IB4 in solution inhibited  7G2-,  B6H12-, 
as well as IB4-stimulated respiratory burst (Figs. 6 and 8 A). 
These data suggested the possibility that CD18-mediated cell 
adhesion  and  spreading might be necessary for LRI/IAP- 
W032 
IB4 
7G2 
Buffer 
0.0  0.2  0.4  0.6  0.8  1.0  1.2  1.4 
nmol H202 
Figure 6.  Inhibition of mAb-stimulated respiratory burst. The ability 
of various mAb and peptides to inhibit the respiratory burst generated 
by PMN adhesion to plate-bound 7G2 (.4) and IB4 (B) were compared. 
7G2, B6H12, and KGAGDV  in solution all inhibited 7G2-stimulated re- 
spiratory burst, whereas controls KGALEV, 2D3, and W6/32 did not 
(.4). None of these reagents inhibited IB4-stimulated respiratory  burst (B). 
IB4 inhibited both 7G2- and IB4-stimulated  respiratory burst. Data shown 
are the mean _+ SEM of measurements at 60 min from three independent 
experiments, each performed in triplicate. 
stimulated respiratory burst.  Alternatively,  IB4 in solution 
might have inhibited because it perturbed normal signal trans- 
duction. In accord with the latter possibility, the inhibitory 
effect of IB4 on B6H12- and 7G2-stimulated respiratory burst 
was blocked entirely by the protein kinase A inhibitor HA1004 
(Fig. 8 A). In contrast, the equally potent inhibition by IB4 
in solution on the effect of solid phase IB4 was unaffected 
by HA1004. The effect of IB4 on LRI-IAP-activated H202 
production was consistent with the previous observation that 
IB4 stimulates  cAMP accumulation in PMN  (22).  Activa- 
tion of the respiratory burst by many agonists is inhibited 
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Figure 7.  Inhibition  of B6H12-stimuhted  respiratory  burst. The ability 
of various mAb and peptides to inhibit the respiratory  burst generated 
by PMN adhesion  to plate-bound  B6H12 was tested. 7G2 and KGAGDV 
in solution  both inhibited  B6H12-stimulated  respiratory  burst, whereas 
W6/32, 2D3, and KGALEV did not. Data shown are the mean +_ SEM 
of measurements  at 60 rain  from  three  independent  experiments,  each  per- 
formed in triplicate. 
by increases in intracellular cAMP (26). We tested the effect 
of  elevation of intracellular CAMP on mAb-stimulated respi- 
ratory burst by adding to the reaction wells Br-CAMP, which 
can cross the plasma membrane and increase  cytoplasmic  cAMP 
concentration. LRI/IAP-stimulated respiratory  burst was 
much more sensitive to exogenous addition of  Br-CAMP than 
CD18-dependent H2Oz production. At 100/~M Br-CAMP, 
LRI/IAP-stimulated respiratory burst was almost completely 
inhibited, whereas CD18-dependent respiratory burst was in- 
hibited by only 16.5% (Fig. 8 A). 
We also examined whether PMN from a well-studied leu- 
kocyte adhesion deficiency (LAD)  patient with the severe 
phenotype (21) could activate the respiratory burst in response 
to KGAGDV-,  7G2-,  or B6H12-coated surfaces, the LAD 
PMN made 76  +  3% of the H2Oz made by normal PMN. 
This demonstrated that CD18  was not necessary for the 
LILI/IAP-stimnlated respiratory burst. The 7G2- and B6H12- 
stimulated H202 production was unaffected by IB4 in solu- 
tion, whereas both KGAGDV and B6H12 mAb in solution 
inhibited the LAD PMN respiratory burst (Fig. 8 B). The 
7G2- and B6H12-stimulated respiratory burst of LAD PMN 
was inhibited by Br-cAMP. Taken together, these data dem- 
onstrate that activation of  respiratory burst through LRI/IAP 
is  independent of CD18,  but can be modulated by anti- 
CD18-initiated alterations in intracytoplasmic cAMP con- 
centration. 
To determine the role of the actin cytoskeleton in LRI/IAP- 
dependent HzO2 generation, cytochalasin-B-treated  PMN 
were incubated in 7G2- and B6H12-coated wells. Cytochalasin 
B markedly inhibited respiratory burst activation, as was also 
true for CD18-dependent  PMN activation (Fig. 9). In con- 
trast, phorbol ester-stimulated respiratory burst was unaffected 
by cytochalasin B treatment (Fig. 9). These data demonstrate 
that the actin cytoskeleton has a necessary role in integrin- 
dependent assembly of the respiratory burst oxidase. 
Regulation of lAP/LRI-dependent Respiratory Burst Differs  from 
the CD18-dependent Respiratory Burst.  The difference in re- 
sponse between LRI/IAP- and CD18-initiated  respiratory 
burst to Br-cAMP suggested that the mechanism for signaling 
oxidase assembly might differ between the two integrins. Be- 
cause tyrosine phosphorylation has been implicated in gener- 
ation of the respiratory burst (27-29), cells were treated with 
the tyrosine kinase inhibitors  genestein and herbimicin.  As 
shown in Fig. 9, these kinase inhibitors  effectively blocked 
CD18-dependent  respiratory  burst,  but  had no  effect on 
LRI/IAP-stimulated HzO2 production. The PKC inhibitor 
H7 effectively blocked respiratory burst from either CD18 
or LRI/IAP stimulation, consistent with a role for PKC phos- 
phorylation of cytosolic components during membrane trans- 
location and assembly of the oxidase subunits (30). LRI/IAP- 
stimulated respiratory burst of LAD PMN was also inhibited 
by H7 but unaffected by herbimicin (data not shown). Thus, 
LRI/IAP-mediated respiratory burst is inhibited by cAME 
but insensitive to protein tyrosine kinase inhibitors, whereas 
CD18-dependent  respiratory burst has the opposite pheno- 
type. These data demonstrate that LRI and CD18 integrins 
activate the NADPH oxidase  by distinct but overlapping  signal 
transduction pathways. 
Discussion 
In this work we have examined the ability of the LKI/IAP 
signal transduction pathway to stimulate phagocyte respira- 
tory burst and have used this function to examine the inter- 
action of LRI and IAP. When adherent to a surface, the LKI 
ligands entactin and KGAGDV can activate the respiratory 
burst in PMN and monocytes. This makes these ligands quite 
different from other integrin ligands which do not activate 
the respiratory  burst on their own (4, 31). Although the reason 
for this is unknown at present, respiratory burst activation 
by these ligands is consistent with the observation that LRI 
binding of entactin and KGAGDV does not require prior PMN 
activation (9), unlike fll or/32 integrin-mediated adhesion. 
These other leukocyte integrins are thought to exist in a low 
affinity state on resting cells and to achieve substantial ligand 
binding affinity only after the ceils have received an additional 
activating signal (32, 33). The discovery that this is not the 
case for LRI has led to the hypotheses that LKI is constitu- 
tively active and that LKI-entactin interaction  represents a 
very early step in leukocyte extravasation to sites of inflam- 
mation. The lack of a requirement for cell activation to achieve 
KGD-dependent ligand binding by LKI may explain both 
the direct activation of the respiratory burst by LKI ligands 
and the lack of the lag phase which has been observed during 
the B2-dependent respiratory  burst elicited by TNF-c~ or 
F-Met-Leu-Phe in PMN adherent to extracellular matrix pro- 
teins. 
In the fluid phase, LKI ligands cannot activate the respira- 
tory burst, even  when they are multivalent, as in the branched 
KGAGDV peptide. In this regard, activation of the respira- 
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stimulated by these mAb. This is consistent with previous data that IB4 can stimulate cAMP generation by PMN (22). HA1004 had no effect on 
IB4 inhibition  of IB4-stimulated respiratory burst. The respiratory bursts stimulated by both B6H12 and 7G2 are sensitive to 100/~M Br-cAMP, whereas 
that stimulated by IB4 is not. At 500 ttM Br-cAMP also inhibited the IB4-stimulated respiratory burst (data not shown). Data shown are the mean 
_+ SEM of measurements done at 60 min from three independent experiments, each done in triplicate. (B) Respiratory burst stimulated by plate-bound 
7G2 and B6H12 in LAD PMN. LAD PMN were incubated with LKI/IAP ligands and tested for respiratory burst and inhibition  by fluid phase ligands 
as in Fig. 6. KGAGDV peptide and B6H12 mAb in the fluid phase inhibit the respiratory burst from LAD PMN, but IB4 does not. W6/32 (anti-HLA)- 
and 2D3 (noninhibitory  anti-IAP)-coated surfaces did not stimulate a respiratory burst in LAD PMN (data not shown). Data are from a single experiment 
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CD18-dependent respiratory  burst. The effects of  cytochalasin  B (2.5/~g/ml), 
and the protein kinase inhibitors genestein (50/~g/ml), herbimicin (10 
/zg/ml), and H-7 (300 riM) on mAb-stimulated  respiratory burst were ex- 
amined.  Cytochalasin B and H-7 inhibited both LRI/IAP- and CD18- 
dependent pathways for generation of the respiratory burst. In contrast, 
the tyrosine kinase inhibitors genestein and herbimicin affected CD18- 
dependent H202 production preferentially. The H-7 dose used to inhibit 
PMA-stimulated respiratory burst was 650 nM; for the other stimuli 300 
nM H-7 was used. Data shown are the mean _+  SEM of measurements 
done at 60 min from three independent experiments, each done in triplicate. 
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tory burst differs from stimulation of Fc receptor-mediated 
phagocytosis, which can be activated by fluid phase LRI ligands 
(1, 2, 8, 22). This suggests that LRI ligation is not sufficient 
to activate the respiratory burst, and that the cytoskeletal rear- 
rangements that accompany adhesion provide additional re- 
quired signals. It is possible that the difference between this 
assay system  and stimulated  phagocytosis  is  that  IgG  Fc 
receptor  ligation during phagocytosis provides  some addi- 
tional biochemical signals for cell activation.  Adhesion itself 
may play a similar role during generation of the respiratory 
burst. For many cells, including PMN, integrin-mediated adhe- 
sion is known to have this priming or enhancing role on signal 
transduction pathways  (4,  5,  26,  27,  34,  35). 
Some anti-LRI and anti-lAP antibodies are equally capable 
as LRI ligands for activating the respiratory burst. Only anti- 
LRI and anti-lAP antibodies  which when in solution can 
inhibit ligand activation are capable of activating phagocytes 
themselves when surface adherent. This suggests that simple 
aggregation of these antigens on the adherent surface of the 
cells is not sufficient to activate the respiratory burst. Rather, 
some essential signal must be provided by the surface-bound 
antibodies.  Possibly, the antibodies  stabilize a conformation 
of LKI or IAP capable of transducing a signal when ag- 
gregated.  This hypothesis is consistent with data showing that integrins (36-40) and lAP (25) can exist in different con- 
formations in the plasma membrane. LRI ligands and anti- 
LRI antibody in solution inhibited the respiratory burst gener- 
ated from anti-lAP-coated surfaces. This suggests that direct 
interaction with IAP does not bypass the integrin receptor 
in the signal transduction pathway for phagocyte activation. 
Rather, inhibitory reagents directed at either LRI or IAP can 
prevent activation stimulated by ligation of the other com- 
ponent. These data suggest a model in which LRI and IAP 
act as a signal transduction unit. This is consistent with a 
physical interaction between LRI and IAP as has been shown 
for ccvB3 and IAP (2).  This hypothesis is analogous to that 
suggested  for  signal  transduction  from  several  cytokine 
receptors which interact with additional, nonligand binding 
plasma membrane proteins. Interaction with these additional 
components not only regulates ligand affinity, but also is re- 
quired for cytokine effects on the target cells (11-15, 41, 42). 
Thus,  the role for IAP may be to regulate ligand binding 
and integrin-mediated signal transduction for receptors of the 
LRI/fl3 family. 
Finally, these data demonstrate that the adhesion-dependent 
respiratory burst induced by the LRI/IAP complex is CD18 
independent and proceeds by a signal transduction pathway 
distinct from that activated by CD18 ligation. Whereas CD18- 
independent adhesion in PMN has been described, its bio- 
logical role has been unexamined until now (9, 43, 44). Soluble 
anti-CD18 fails to inhibit the LRI/IAP-dependent respira- 
tory burst in LAD PMN and in normal PMN in the pres- 
ence of the protein kinase A inhibitor HA1004. Since HA1004 
does not block CD18-dependent adhesion (Fig. 8 A) or phago- 
cytosis (22), these experiments show that, although LRI/IAP- 
generated H202 production requires adhesion, it is CD18 in- 
dependent. This is consistent with previous data that PMN 
adhesion to the LRI ligand entactin is CD18 independent 
(9). Moreover, the signal transduction pathway for LRI/IAP 
stimulation of the respiratory burst can be distinguished from 
CD18-dependent respiratory burst. The LRI/IAP-dependent 
oxidative burst is inhibited by exogenous cAMP at concen- 
trations that do not affect CD18-induced H202 production. 
In contrast, the CD18-induced respiratory burst is inhibited 
by low concentrations of tyrosine kinase inhibitors, which 
do not affect the LRI/IAP-induced respiratory burst at all. 
Taken together, these experiments demonstrate immunolog- 
ically and pharmacologically that the LRI/IAP-induced re- 
spiratory burst, although dependent on cell adhesion, is in- 
dependent of CD18. 
In conclusion, this work has elucidated a novel pathway 
for signal transduction and phagocyte activation by extracel- 
lular matrix. This pathway requires not only ligand binding 
by an integrin, the LRI, but also an associated  nonintegrin 
protein which is an integral part of the signal transduction 
complex. Interestingly, this complex can bind to the base- 
ment membrane protein entactin without prior cell activa- 
tion, a feature shared by no other leukocyte integrin, including 
CD18 integrins (43). This feature, and the fact that interac- 
tion of PMN with 7G2- or B6H12-coated surfaces activates 
CD18 integrins (45) suggest that when the endothelial layer 
is not intact or does not make a tight junction, ligand binding 
by LRI/IAP may be a very early step in leukocyte activation 
during diapedesis  into sites of inflammation and infection. 
The LRI/IAP signal transduction pathway may represent an 
important and specific target for intervention in the inflam- 
matory process. 
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